Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Progression‐free survival · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | HR 0.42 [0.33, 0.54] | 3 studies · 540 participants | Moderate |
Intervention NR Secondary malignancies AML/MDS · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | RR 2.87 [0.7, 11.75] | 4 studies · 1023 participants | Low |
Intervention NR Secondary malignancies Solid cancer · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | RR 1.2 [0.25, 5.77] | 3 studies · 701 participants | Low |
Intervention NR Adverse events · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | no estimate extracted | 3 studies · 527 participants | Very low |
Intervention NR Relief of bleedingPictorial bleeding charts · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 17.84 [6.72, 47.38] | 2 studies · 77 participants | Low |
Mifepristone (50 mg/1 day after/3 months) vs placebo Leiomyoma volume(mL). Scale from: 0 to 100. · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Mifepristone (50 mg/1 day after/3 months) vs placebo Cystic glandular dilatationdichotomic · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 16.67 [1.36, 204.03] | 1 study · 19 participants | Low |
Mifepristone (5 mg/day/6 months) vs placebo Relief of bleedingdichotomic · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 2.22 [0.54, 9.13] | 1 study · 42 participants | Low |
Mifepristone (5 mg/day/6 months) vs placebo Leiomyoma volume(mL) · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |
Mifepristone (5 mg/day/6 months) vs placebo Uterine volume(mL) · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |
Intervention NR Reduction in average fibroid volumeScale from: 0 to 100 · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 3 studies · 99 participants | Low |
Intervention NR Reduction in uterine volumeScale from: 0 to 100 · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 2 studies · 72 participants | Low |
Intervention NR Adverse events · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 31.65 [4.83, 207.35] | 2 studies · 54 participants | Low |
Mifepristone (10 mg/day/3 months) vs placebo Leiomyoma volume (mL) · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 1 study · 35 participants | Low |
Mifepristone (10 mg/day/3 months) vs placebo Uterine volume(mL) · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | no estimate extracted | 1 study · 35 participants | Low |
Mifepristone (10 mg/day/3 months) vs placebo Relief of bleedingdichotomic · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 27.02 [7.25, 100.7] | 1 study · 35 participants | Low |
Mifepristone (10 mg/day/3 months) vs placebo Relief of pelvic paindichotomic · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 2.1 [0.38, 11.71] | 1 study · 26 participants | Low |
Mifepristone (10 mg/day/3 months) vs placebo Relief of dysmenorrhoeadichotomic · patients with uterine fibroids Mifepristone for uterine fibroids (2012) · Cochrane | OR 10.93 [2.37, 50.51] | 1 study · 26 participants | Low |
Regular formoterol vs regular salmeterol All‐cause mortality in adults · patients with asthma Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious… (2012) · Cochrane | no estimate extracted | 3 studies · 1116 participants | Low |
Regular formoterol vs regular salmeterol All‐cause mortality in children · patients with asthma Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious… (2012) · Cochrane | no estimate extracted | 1 study · 156 participants | Very low |
Regular formoterol vs regular salmeterol All‐cause SAEs in adults · patients with asthma Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious… (2012) · Cochrane | OR 0.77 [0.46, 1.28] | 3 studies · 1116 participants | Low |
Regular formoterol vs regular salmeterol All‐cause SAEs in children · patients with asthma Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious… (2012) · Cochrane | OR 0.95 [0.06, 15.33] | 1 study · 156 participants | Very low |
Regular formoterol vs regular salmeterol Asthma‐related SAEs in adults · patients with asthma Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious… (2012) · Cochrane | OR 0.86 [0.29, 2.57] | 3 studies · 1116 participants | Low |
Regular formoterol vs regular salmeterol Asthma‐related SAEs in children · patients with asthma Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious… (2012) · Cochrane | no estimate extracted | 1 study · 156 participants | Very low |
Intervention NR Parasitological cure ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.99 [0.95, 1.03] | 10 studies · 932 participants | Moderate |
Intervention NR Parasitological cure ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 1.23 [0.87, 1.73] | 3 studies · 179 participants | Very low |
Intervention NR Clinical improvement ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 1.15 [1, 1.32] | 3 studies · 179 participants | Very low |
Intervention NR Gastrointestinal side effects ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.58 [0.21, 1.62] | 3 studies · 179 participants | Very low |
Intervention NR Neurological side effects ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 1.3 [0.29, 5.92] | 2 studies · 138 participants | Very low |
Intervention NR Serious adverse events · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | no estimate extracted | 3 studies · 179 participants | Ungraded |
Intervention NR Clinical improvement ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.98 [0.93, 1.04] | 5 studies · 483 participants | Moderate |
Intervention NR Gastrointestinal side effects ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.29 [0.13, 0.63] | 8 studies · 717 participants | Moderate |
Intervention NR Neurological side effects ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.34 [0.18, 0.64] | 5 studies · 453 participants | Low |
Intervention NR Parasitological cure ( · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.58 [0.32, 1.06] | 5 studies · 142 participants | Very low |
Intervention NR Clinical improvement · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Side effects: nausea/vomiting · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.32 [0.05, 1.9] | 3 studies · 100 participants | Very low |
Intervention NR Side effects: headache · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | RR 0.24 [0.03, 2.06] | 2 studies · 74 participants | Very low |
Intervention NR Serious adverse events · People with giardiasis infection Drugs for treating giardiasis (2012) · Cochrane | no estimate extracted | 5 studies · 142 participants | Ungraded |
Intervention NR Death from any cause · Patients with type 2 diabetes mellitus Momordica charantia for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · Patients with type 2 diabetes mellitus Momordica charantia for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects ( · Patients with type 2 diabetes mellitus Momordica charantia for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | 4 studies · 479 participants | Low |
Intervention NR Health‐related quality of life · Patients with type 2 diabetes mellitus Momordica charantia for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · Patients with type 2 diabetes mellitus Momordica charantia for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in HbA1c from baseline to endpoint ( · Patients with type 2 diabetes mellitus Momordica charantia for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Intervention NR Oesophageal cancer‐specific mortality ‐ not measured · patients with oesophageal cancer Screening for oesophageal cancer (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary outcomes ‐ not measured · patients with oesophageal cancer Screening for oesophageal cancer (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Febrile neutropenia Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.27 [0.11, 0.7] | 6 studies · 2073 participants | Moderate |
Intervention NR Injection‐site reaction Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 3.59 [2.33, 5.53] | 2 studies · 262 participants | Moderate |
Intervention NR Early mortality Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.32 [0.13, 0.77] | 8 studies · 2143 participants | Low |
Intervention NR Infection‐related mortality Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.14 [0.02, 1.29] | 8 studies · 2143 participants | Low |